Compound ID | 1860
Synonym(s): Rifamycin SV | Rifocin | Aemcolo
Class: Rifamycin
Spectrum of activity: | Gram-positive & Gram-negative |
Details of activity: | Inhibits bacterial DNA-dependent RNA polymerase, thus inhibiting bacterial RNA synthesis |
Propensity to select resistant mutants: | Yes |
Description: | Streptomyces natural compound (Amycolatopsis rifamycinica). Used for traveler's diarrhea in oral formulation |
Institute where first reported: | Cosmo Technologies Ltd, Dr. Falk Pharma Gmbh;; Redhill |
Year first mentioned: | 1957 |
Highest developmental phase: | Approved by FDA in 2018 |
Development status: | Discontinued |
Chemical structure(s): | |
Canonical SMILES: | C[C@H]1/C=C/C=C(/C)\C(=O)NC2=C(C3=C(C(=C4C(=C3C(=C2)O)C(=O)[C@@](C)(O/C=C/[C@@H]([C@@H](C)[C@H]([C@H](C)[C@@H]([C@H](C)[C@H]1O)O)OC(=O)C)OC)O4)C)O)O |
Isomeric SMILES: | C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C |
InChI: | InChI=1S/C37H47NO12/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46)/b11-10+,14-13+,17-12-/t16-,18+,19+,20+,25-,29-,30+,33+,37-/m0/s1 |
InChI Key: | HJYYPODYNSCCOU-ODRIEIDWSA-N |
Structure link: | https://pubchem.ncbi.nlm.nih.gov/compound/6324616 |
External links: | |
Guide to Pharmacology: | rifamycin SV |
Main Source: | https://pubs.acs.org/doi/10.1021/cr030112j |
Citations: |
|